Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer
Life · 30.03.2026 · 16 (4) · 564
DOI: 10.3390/life16040564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 30.03.2026. Verfasst von Min-Chi Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 114, …. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tri-Service General Hospital.
Abstract (Originalsprache)
Background
The optimal sequencing of regorafenib and trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal cancer (mCRC) remains uncertain, particularly in Asian populations.
Methods
We retrospectively analyzed 110 patients with mCRC who sequentially received both agents between 2011 and 2025. Patients were categorized into regorafenib followed by FTD/TPI (Rego → FTD/TPI, n = 88) and FTD/TPI followed by regorafenib (FTD/TPI → Rego, n = 22). Co-primary endpoints were time to treatment discontinuation (TTD) and overall survival (OS). Propensity score-based weighting methods, including stabilized inverse probability of treatment weighting (primary analysis), were used to adjust for baseline imbalances. Multivariable Cox regression was performed as a sensitivity analysis.
Results
No statistically significant differences were observed between treatment sequences. In the primary analysis, the hazard ratio (HR) for TTD was 1.01 (95% CI 0.71–1.43), and for OS was 1.19 (95% CI 0.67–2.12), with FTD/TPI → Rego as reference. Median TTD was 6.8 versus 8.9 months, and median OS was 14.6 versus 20.2 months, respectively.
Conclusions
Clinical outcomes were comparable regardless of treatment order, supporting individualized sequencing decisions in refractory mCRC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Hematology and Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan.
- Department of Oncology, Tri-Service General Hospital, National Defense Medical University, Taipei 114, Taiwan.
ORCID-Profile: Min-Chi Cheng, Po-Huang Chen, Shiue-Wei Lai, Ming-Shen Dai
Förderung
- Tri-Service General Hospital
Zitieren
APA
Cheng, M. C., Chen, P. H., Chen, Y. G., Lai, S. W., Chen, J. H., Dai, M. S., & Chang, P. Y. (2026). Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer. Life, 16(4), 564. https://doi.org/10.3390/life16040564
Vancouver
Cheng MC, Chen PH, Chen YG, Lai SW, Chen JH, Dai MS, et al. Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer. Life. 2026;16(4):564. doi:10.3390/life16040564
BibTeX
@article{Cheng2026,
author = {Cheng, Min-Chi and Chen, Po-Huang and Chen, Yu-Guang and Lai, Shiue-Wei and Chen, Jia-Hong and Dai, Ming-Shen and Chang, Ping-Ying},
title = {Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer},
journal = {Life},
year = {2026},
volume = {16},
number = {4},
pages = {564},
doi = {10.3390/life16040564}
}
EUVIMED